MXPA05008394A - Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma. - Google Patents

Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma.

Info

Publication number
MXPA05008394A
MXPA05008394A MXPA05008394A MXPA05008394A MXPA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A MX PA05008394 A MXPA05008394 A MX PA05008394A
Authority
MX
Mexico
Prior art keywords
glaucoma
diagnosis
diabetic neuropathy
cataract
cataracts
Prior art date
Application number
MXPA05008394A
Other languages
Spanish (es)
Inventor
Lang Florian
Original Assignee
Lang Florian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lang Florian filed Critical Lang Florian
Publication of MXPA05008394A publication Critical patent/MXPA05008394A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the use of a functional inhibitor of hsgk1or hsgk3 protein or a negative transcription regulator of the hsgk1 or hsgk3 gene in the production of a medicament for the treatment and/or prophylaxis of a cataract, glaucoma or diabetic neuropathy. Another aspect of the invention relates to the use of a single-stranded or double-stranded nucleic acid comprising the hsgk1 sequence according to Acc No. NM 005627 or one of the fragments thereof or comprising the hsgk3 sequence according to Acc. No. AF169035 or one of the fragments thereof in the diagnosis of a predisposition to the formation of a cataract, glaucoma and/or diabetic neuropathy, in addition to a kit for diagnosis of a predisposition to the formation of a cataract, glaucoma and/or diabetic neuropathy, comprising the above-mentioned nucleic acid. The invention further relates to various screening methods for identifying and characterizing therapeutically effective substances from a plurality of test substances for the treatment and/or prophylaxis of at least one disease selected from cataracts, glaucoma or diabetic neuropathy.
MXPA05008394A 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma. MXPA05008394A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (en) 2003-02-07 2003-02-07 Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
PCT/EP2004/001048 WO2004069258A2 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Publications (1)

Publication Number Publication Date
MXPA05008394A true MXPA05008394A (en) 2005-10-05

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008394A MXPA05008394A (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma.

Country Status (13)

Country Link
EP (1) EP1663246A2 (en)
JP (1) JP2006519189A (en)
KR (1) KR20050114214A (en)
CN (1) CN1771039A (en)
AU (1) AU2004210416A1 (en)
BR (1) BRPI0407300A (en)
CA (1) CA2514703A1 (en)
DE (1) DE10305212A1 (en)
MX (1) MXPA05008394A (en)
PL (1) PL378399A1 (en)
RU (1) RU2005127808A (en)
WO (1) WO2004069258A2 (en)
ZA (1) ZA200506280B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006135654A (en) * 2004-03-11 2008-09-10 Мерк Патент ГмбХ (DE) METHODS FOR MODULATION OF GLUTAMATE RECEPTORS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS, INCLUDING THE APPLICATION OF SERUM AND KLUCKORTICOID KINASE MODULATORS
CA2559141A1 (en) * 2004-03-11 2005-10-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for interfering with fibrosis
DE102004059781A1 (en) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Use of serum / glucocorticoid-regulated kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
JPWO2007037560A1 (en) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Therapeutic or diagnostic use of SGK2 gene
JP5249774B2 (en) * 2005-11-22 2013-07-31 マギル ユニバーシティ Intraocular pressure regulation early genes and use thereof
US20080153903A1 (en) * 2006-12-22 2008-06-26 Alcon Manufacturing, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
AU2012209455B2 (en) * 2011-01-25 2017-05-04 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
KR102357260B1 (en) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 Method for diagnosis and predict of diabetic neuropathy using micro-rna and kit therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382061T1 (en) * 1994-08-30 2008-01-15 Univ Dundee AGENTS FOR THE INDUCTION OF APOPTOSIS AND FOR THERAPY USE
AU6263996A (en) * 1995-06-07 1996-12-30 Ligand Pharmaceuticals Incorporated Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (en) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Cell volume regulated human kinase h-sgk
AU3991499A (en) * 1998-05-15 1999-12-06 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
JP2002533063A (en) * 1998-12-14 2002-10-08 ザ、ユニバーシティー、オブ、ダンディー Method
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (en) * 1999-04-20 2000-11-02 Florian Lang Medicament containing inhibitors of cell volume regulated human kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets

Also Published As

Publication number Publication date
DE10305212A1 (en) 2004-08-19
CA2514703A1 (en) 2004-08-19
AU2004210416A1 (en) 2004-08-19
WO2004069258A2 (en) 2004-08-19
PL378399A1 (en) 2006-04-03
CN1771039A (en) 2006-05-10
ZA200506280B (en) 2006-05-31
BRPI0407300A (en) 2006-02-07
WO2004069258A3 (en) 2005-02-24
RU2005127808A (en) 2006-05-27
KR20050114214A (en) 2005-12-05
JP2006519189A (en) 2006-08-24
EP1663246A2 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
Mangold et al. Sexually divergent induction of microglial-associated neuroinflammation with hippocampal aging
Hattori et al. Demyelinating and axonal features of Charcot–Marie–Tooth disease with mutations of myelin‐related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients
Bredel et al. Tumor necrosis factor-α–induced protein 3 as a putative regulator of nuclear factor-κB–mediated Resistance to O6-alkylating agents in human glioblastomas
Tanaka et al. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system
EP2820131A2 (en) Use of micro-rnas or genes as markers for the identification, diagnosis and therapy of individual forms of non-ischemic cardiomyopathies or storage diseases of the heart
Scholz et al. Dependency of intraocular pressure elevation and glaucomatous changes in DBA/2J and DBA/2J-Rj mice
MXPA05008394A (en) Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma.
WO2005067391A3 (en) Diagnostic test for parkinson's disease
ATE432997T1 (en) THERAPY MONITORING FOR TUMORS USING ACC133 MRNA
JP5769084B2 (en) Methods for inhibiting CAG elongation gene product expression and gene product expression and aggregation, as well as methods for identifying agents that are useful for inhibition
Kosior-Jarecka et al. MicroRNAs in the aqueous humor of patients with different types of glaucoma
Bua et al. Diagnostic markers for glaucoma: a patent and literature review (2013-2019)
US20180318285A1 (en) Methods for treatment of autism spectrum disorders
Wang et al. Dysregulation of antimicrobial peptide expression distinguishes Alzheimer’s disease from normal aging
Wang et al. Cytotoxic effect of interleukin-8 in retinal ganglion cells and its possible mechanisms
Handler et al. Decreasing mutant ATXN1 nuclear localization improves a spectrum of SCA1-like phenotypes and brain region transcriptomic profiles
CN108354944A (en) SiRNA and its for treating and/or preventing the application in the method and composition of eye disorders
Ambler et al. Microarray expression profiling in adhesion and normal peritoneal tissues
Pandav et al. Lack of association between lysyl oxidase-like 1 polymorphism in pseudoexfoliation syndrome and pseudoexfoliation glaucoma in North Indian population
Rampazzo et al. Hormographiella aspergillata keratomycosis in a dog
Pappadà et al. Suppressing gain-of-function proteins via CRISPR/Cas9 system in SCA1 cells
Truby et al. A zinc finger transcription factor tunes social behaviors by controlling transposable elements and immune response in prefrontal cortex
Saddala et al. RNA-seq data from CXC chemokine receptor type 5 (CXCR5) gene knockout aged mice with retinal degeneration phenotype
Shastry Emerging concept of genetic and epigenetic contribution to the manifestation of glaucoma
Dutrow et al. The Human Accelerated Region HACNS1 modifies developmental gene expression in humanized mice